Market Cap | 4.19M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -5.69M | Forward P/E | -0.13 | EPS next Y | - | 50D Avg Chg | 2.00% |
Sales | 8.01M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -44.00% |
Dividend | N/A | Price/Book | 0.43 | EPS next 5Y | - | 52W High Chg | -83.00% |
Recommedations | 2.00 | Quick Ratio | 6.59 | Shares Outstanding | 5.97M | 52W Low Chg | 58.00% |
Insider Own | 1.60% | ROA | -36.37% | Shares Float | 4.81M | Beta | 0.49 |
Inst Own | 18.25% | ROE | -66.50% | Shares Shorted/Prior | 50.18K/26.46K | Price | 0.71 |
Gross Margin | 60.26% | Profit Margin | -71.12% | Avg. Volume | 850,356 | Target Price | - |
Oper. Margin | -79.44% | Earnings Date | May 8 | Volume | 75,148 | Change | -2.22% |
Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Exploration Capital, LLC | Director Director | Jan 09 | Buy | 0.98 | 51,502 | 50,472 | 830,004 | 01/11/24 |
Exploration Capital, LLC | Director Director | Jan 03 | Buy | 0.9 | 78,502 | 70,652 | 778,502 | 01/05/24 |
Exploration Capital, LLC | Director Director | Dec 20 | Buy | 0.84 | 47,000 | 39,480 | 47,000 | 12/20/23 |
Exploration Capital Fund, LP | Director Director | Dec 04 | Buy | 0.87 | 30,000 | 26,100 | 700,000 | 12/06/23 |